McClurg, a veteran of 30 years in the space of financial leadership, has held the role of CFO for companies including Orthomet, Incisive Surgical, Video Sentry and Insignia Systems, having begun his career in public accounting at Ernst and Young, according to a news release.
“Over the past quarter, the company has made great progress in achieving key milestones and building our infrastructure,” NeuroOne president & CEO Dave Rosa said in the release. “With our future goal to uplist to a major national securities exchange, it became critical to add a seasoned senior financial executive such as Ron.
“His broad experience with both public and private companies as well as his familiarity with medical device companies make him an ideal fit for the role of CFO at NeuroOne. We are very fortunate to have him as part of the NeuroOne family and look forward to working with him.”
Eden Prairie, Minn.-based NeuroOne, a medtech company developing surgical care options for patients suffering from neurological disorders, received FDA clearance for its Evo cortical electrode technology in November 2019.
The company said in the release that it is planning to submit for 510(k) clearance for its sEEG electrode technology for recording, monitoring and stimulating brain tissue in the first half of this year.
NeuroOne is also continuing development for therapeutic electrode technology for use in Parkinson’s Disease, epilepsy and back pain due to failed back surgery.
“I’m excited to join the NeuroOne team because I believe in the company’s growth strategy to improve outcomes for patients suffering from neurological disorders and enhance shareholder value,” McClurg said. “I feel that my skills and experience will complement those of the rest of the NeuroOne leadership team.”